Validation of NTRK Fusion Detection Using an Ultrarapid, Fully Automated Cartridge-based PCR Assay.
A bedside-compatible rapid test identifies cancer patients eligible for targeted TRK inhibitor therapy, bypassing delays from sending samples to distant laboratories.
A validation study of an ultrarapid, fully automated cartridge-based PCR assay for detecting NTRK gene fusions — the companion diagnostic biomarker for TRK inhibitor therapy across cancer types — demonstrates analytical concordance with reference methods. Rapid bedside-compatible NTRK testing could accelerate precision oncology deployment in settings lacking NGS infrastructure.
What the study was
- Study design
- Validation study of a diagnostic assay
- Population
- Tumor samples from patients with various cancer types requiring NTRK fusion testing
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- The Journal of Molecular Diagnostics
Why it surfaced
Validated companion diagnostic assay enabling rapid NTRK fusion detection for TRK inhibitor selection across cancer types — directly supports precision oncology deployment.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.